Literature DB >> 18415194

[Opioids in "non-malignant" pain-results of long-term treatment in patients with rheumatic disease.].

J Sorge1, B Steffmann, C Lehmkuhl, I Pichlmayr.   

Abstract

The oral administration of strong opioids like morphine is a very effective treatment in cancer pain. However, these analgesics are rarely prescribed for patients suffering from severe "non-malignant" pain. We examined the effects of oral opioids (morphine sulphate tablets, buprenorphine and levomethadone) given to patients with intractable rheumatic pain, which were refractory to other therapeutic measures. The origin of pain was inflammation or a degenerative lesion of the spine. Within a period of more than 3 years, 12 patients were treated accordingly. In 9 patients we could achieve sufficient pain relief, two of them showing improvement only after having changed the initially prescribed drug. We had to stop opioid medication in two patients because of side-effects and, moreover, in one patient because of failure to produce analgesia. 775 weeks of treatment were documented until December 31th, 1990, with an individual duration ranging from 11 to 145 weeks. It was necessary to increase the dose of morphine in the course of treatment of one patient, who is up to now being treated for more than 77 weeks. In all other patients the doses were either stable or varied. No severe side-effects such as respiratory depression were associated with long-term opioid therapy. Constipation was observed in 4 patients, nausea in two patients and urinary retention in one patient. These side-effects could be well treated by an additional medication. No drug abuse, dependence or tolerance were observed. Strong opioids are not analgesics of first choice in patients with rheumatic disease, but an opioid medication should be considered-as well as in patients with intractable pain caused by another disease-when alternative therapeutic measures have failed. The principles of opioid medication in rheumatic pain are similar to those in patients with cancer pain.

Entities:  

Year:  1991        PMID: 18415194     DOI: 10.1007/BF02529469

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  27 in total

1.  [Not Available].

Authors:  W Keup
Journal:  Schmerz       Date:  1988-09       Impact factor: 1.107

2.  [Not Available].

Authors:  M Mumenthaler
Journal:  Schmerz       Date:  1988-03       Impact factor: 1.107

3.  Morphine tolerance as habituation.

Authors:  T B Baker; S T Tiffany
Journal:  Psychol Rev       Date:  1985-01       Impact factor: 8.934

4.  Patterns of narcotic drug use in a cancer pain clinic.

Authors:  R M Kanner; K M Foley
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

5.  Addiction rare in patients treated with narcotics.

Authors:  J Porter; H Jick
Journal:  N Engl J Med       Date:  1980-01-10       Impact factor: 91.245

6.  [Long-term use of narcotics in pain therapy].

Authors:  J G Gostomzyk; W D Heller
Journal:  Dtsch Med Wochenschr       Date:  1990-05-18       Impact factor: 0.628

7.  [Intractable cancer pain as a reason for referral : Analysis of pain etiology and previous drug treatment.].

Authors:  S Grond; D Zech; H Dahlmann; S A Schug; B Stobbe; K A Lehmann
Journal:  Schmerz       Date:  1990-12       Impact factor: 1.107

8.  Modification of morphine tolerance by behavioral variables.

Authors:  C A Sannerud; A M Young
Journal:  J Pharmacol Exp Ther       Date:  1986-04       Impact factor: 4.030

9.  Chronic use of opioid analgesics in non-malignant pain: report of 38 cases.

Authors:  Russell K Portenoy; Kathleen M Foley
Journal:  Pain       Date:  1986-05       Impact factor: 6.961

Review 10.  Chronic opioid therapy in nonmalignant pain.

Authors:  R K Portenoy
Journal:  J Pain Symptom Manage       Date:  1990-02       Impact factor: 3.612

View more
  4 in total

1.  [Not Available].

Authors:  M Zimmermann
Journal:  Schmerz       Date:  1992-03       Impact factor: 1.107

2.  Opioids for chronic pain of non-malignant origin--caring or crippling.

Authors:  R G Large; S A Schug
Journal:  Health Care Anal       Date:  1995-02

3.  [Pain treatment with dihydrocodeine slow release. Results of a post marketing surveillance study.].

Authors:  M Zimmermann; H Arnau; M Hepper
Journal:  Schmerz       Date:  1995-07       Impact factor: 1.107

4.  [Not Available].

Authors:  J Sorge; H Menninger; U Thoden; E Hackenthal
Journal:  Schmerz       Date:  1992-09       Impact factor: 1.107

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.